Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
| Autor: | Saleh, M., Barve, M., Subbiah, V., Papadopoulos, K.P., Morgensztern, D., Mettu, N.B., Roychowdhury, S., Spanggaard, I., Veronese, M.L., Tian, C., Silverman, I.M., Gutierrez, M. |
|---|---|
| Zdroj: | In ESMO Open July 2024 9(7) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|